TNF and rheumatoid arthritis: First, it provides a longitudinal comparison of serum calprotectin and CRP, across three clinically relevant timepoints, in patients with RA treated with distinct targeted therapies (IL-6 receptor inhibitor, TNFα inhibitor, and JAK inhibitor).